| First Author | Yadav V | Year | 2019 |
| Journal | J Clin Invest | Volume | 129 |
| Issue | 7 | Pages | 2872-2877 |
| PubMed ID | 30990798 | Mgi Jnum | J:291202 |
| Mgi Id | MGI:6442970 | Doi | 10.1172/JCI124804 |
| Citation | Yadav V, et al. (2019) Ectonucleotidase tri(di)phosphohydrolase-1 (ENTPD-1) disrupts inflammasome/interleukin 1beta-driven venous thrombosis. J Clin Invest 129(7):2872-2877 |
| abstractText | Deep vein thrombosis (DVT), caused by alterations in venous homeostasis is the third most common cause of cardiovascular mortality; however, key molecular determinants in venous thrombosis have not been fully elucidated. Several lines of evidence indicate that DVT occurs at the intersection of dysregulated inflammation and coagulation. The enzyme ectonucleoside tri(di)phosphohydrolase (ENTPD1, also known as CD39) is a vascular ecto-apyrase on the surface of leukocytes and the endothelium that inhibits intravascular inflammation and thrombosis by hydrolysis of phosphodiester bonds from nucleotides released by activated cells. Here, we evaluated the contribution of CD39 to venous thrombosis in a restricted-flow model of murine inferior vena cava stenosis. CD39-deficiency conferred a >2-fold increase in venous thrombogenesis, characterized by increased leukocyte engagement, neutrophil extracellular trap formation, fibrin, and local activation of tissue factor in the thrombotic milieu. This was orchestrated by increased phosphorylation of the p65 subunit of NFkappaB, activation of the NLRP3 inflammasome, and interleukin-1beta (IL-1beta) release in CD39-deficient mice. Substantiating these findings, an IL-1beta-neutralizing antibody attenuated the thrombosis risk in CD39-deficient mice. These data demonstrate that IL-1beta is a key accelerant of venous thrombo-inflammation, which can be suppressed by CD39. CD39 inhibits in vivo crosstalk between inflammation and coagulation pathways, and is a critical vascular checkpoint in venous thrombosis. |
